Altered Metabolic Phenotypes and Hypothalamic Neuronal Activity Triggered by Sodium-Glucose Cotransporter 2 Inhibition

نویسندگان

چکیده

BackgroundSodium-glucose cotransporter 2 (SGLT-2) inhibitors are currently used to treat patients with diabetes. Previous studies have demonstrated that treatment SGLT-2 is accompanied by altered metabolic phenotypes. However, it has not been investigated whether the hypothalamic circuit participates in development of compensatory phenotypes triggered inhibitors. MethodsMice were fed a standard diet or high-fat and treated dapagliflozin, an inhibitor. Food intake energy expenditure observed using indirect calorimetry system. The activity neurons response dapagliflozin was evaluated immunohistochemistry c-Fos antibody. Quantitative real-time polymerase chain reaction performed determine gene expression patterns hypothalamus dapagliflozin-treated mice. ResultsDapagliflozin-treated mice displayed enhanced food reduced expenditure. Altered neuronal activities multiple nuclei association appetite regulation. Additionally, we found elevated immunosignals agouti-related peptide paraventricular nucleus hypothalamus. ConclusionThis study suggests functional involvement induced inhibitor treatment.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review

UNLABELLED Blood glucose-lowering treatment options generally target insulin action or beta-cell function. In diabetes, expression of the sodium-glucose cotransporter-2 (SGLT2) genes is up-regulated and renal threshold increased, resulting in increased glucose reabsorption from glomerular filtrate, reducing urinary glucose excretion and worsening the hyperglycemic condition. The SGLT2 inhibitor...

متن کامل

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.

BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors lower glycemia by enhancing urinary glucose excretion. The physiologic response to pharmacologically induced acute or chronic glycosuria has not been investigated in human diabetes. METHODS We evaluated 66 patients with type 2 diabetes (62 ± 7 years, BMI = 31.6 ± 4.6 kg/m(2), HbA1c = 55 ± 8 mmol/mol, mean ± SD) at baseline, after a ...

متن کامل

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition

OBJECTIVE Sodium-glucose cotransporter 2 (SGLT2) inhibitors cause substantially less weight loss than expected from the energy excreted via glycosuria. Our aim was to analyze this phenomenon quantitatively. RESEARCH DESIGN AND METHODS Eighty-six patients with type 2 diabetes (HbA1c 7.8 ± 0.8% [62 ± 9 mmol/mol], estimated glomerular filtration rate [eGFR] 89 ± 19 mL ⋅ min(-1) ⋅ 1.73 m(-2)) rec...

متن کامل

Energy Balance After Sodium Glucose Cotransporter 2 (SGLT2) Inhibition

Eighty-six patients with type 2 diabetes (HbA1c = 7.86 0.8% [62 6 9 mmol/mol], estimated glomerular filtration rate [eGFR] = 89 6 19 mL · min · 1.73 m) received empagliflozin (25 mg/day) for 90 weeks with frequent (n = 11) assessments of body weight, eGFR, and fasting plasma glucose (FPG). Time-dependent glucose filtration was calculated as the product of eGFR and FPG; time-dependent glycosuria...

متن کامل

Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?

Diabetic nephropathy is the most common cause of end-stage renal disease requiring chronic dialysis or renal transplantation, resulting in high morbidity, mortality and societal costs to Canadians. Unfortunately, glycemic targets are often not achieved, and existing medications that block the renin-angiotensin-aldosterone system only offer partial protection against the development of renal and...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Diabetes & Metabolism Journal

سال: 2023

ISSN: ['2233-6087', '2233-6079']

DOI: https://doi.org/10.4093/dmj.2022.0261